pharmaphorum

MARCH 1, 2024

Pfizer says new oncology division will generate eight new blockbusters by 2030, in first R&D update after its $43bn takeover of Seagen.

133

133

STAT

OCTOBER 27, 2023

The American College of Emergency Physicians predicted in a 2021 study that there would be a surplus of nearly 8,000 emergency physicians by 2030. While much of the health care workforce is battling staff shortages, the emergency medicine field is trying to figure out how to manage a potential oversupply of physicians. Read the rest…

Hospitals 354

Hospitals 354

pharmaphorum

MAY 21, 2024

AstraZeneca CEO Pascal Soriot says group revenues can reach $80bn by 2030, fuelled by a pipeline that features 'many' potential $5bn-plus candidates.

119

119

Express Pharma

MAY 21, 2024

AstraZeneca aims to reach $80 billion in revenue by 2030, up from $45.8 To drive sustained growth beyond 2030, the company will invest in new technologies and platforms. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for $80 billion by 2030.” “We

108

108

World Pharma News

MAY 21, 2024

Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 To drive sustained growth beyond 2030, the Company will continue investing in transformative new technologies and platforms that will shape the future of medicine. billion in 2023.

111

111

STAT

OCTOBER 22, 2024

The experts charged with advising federal health officials on the 2025-2030 Dietary Guidelines for Americans had to scale a mountain of research challenges like this basic impediment, starting with the impossibility of randomly assigning people to eat only x or y for 30 to 40 years. People eat foods, not nutrients.

335

335

pharmaphorum

OCTOBER 26, 2020

CRA’s Life Sciences Practice recently conducted an analysis of the barriers that currently limit reimbursement for many preventive care services and how the evolution of healthcare systems and preventive care offerings could change the demand and uptake of preventive care by 2030. How could payer views change by 2030?

Vaccines 130

Vaccines 130

STAT

APRIL 24, 2024

A rise in the number of younger Americans diagnosed with colorectal cancer worries me — early-age onset colorectal cancer is expected to surge by more than 140% by 2030. As a gastroenterologist and cancer researcher, my mission is to help my patients live longer, healthier, and cancer-free lives.

347

347

STAT

DECEMBER 5, 2023

Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030. Plenty of people in pharma and at the banks that invest in it seem to think so. Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical. 

Drug Pricing 315

Drug Pricing Drug Development 315

Express Pharma

SEPTEMBER 18, 2024

billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. billion by 2030. Despite its forecasted sales performance paling in comparison to Pluvicto by 2030, the use of alpha-emitting actinium-225 could prove to be the future of RLTs in this therapeutic landscape.

Chemotherapy 105

Chemotherapy Labelling Pharmaceutical Companies Pharmaceutical Companies 105

European Pharmaceutical Review

MARCH 28, 2024

billion by 2030. percent between 2024-2030. by 2030 appeared first on European Pharmaceutical Review. The global pharmaceutical and biotechnology environmental monitoring market valued $24 billion in 2023, according to a report by Verified Market Research. This figure is projected to increase to $38.1 PerkinElmer, Inc.

98

98

PharmaVoice

FEBRUARY 20, 2024

By 2030, the AI market is expected to reach $187.95 A significant growth is predicted for both AI and IoT in healthcare. billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

260

260

European Pharmaceutical Review

OCTOBER 18, 2022

billion by 2030, according to a market report. The Asia Pacific region is expected to register the fastest growth from 2022-2030 due to the presence of the large HPAPI manufacturers in China. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65

Dosage 105

Dosage Vaccines 105

STAT

MAY 21, 2024

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

335

335

Pharma Times

NOVEMBER 30, 2021

Following its recent approval of an injectable HIV-1 treatment from the National institute for Health and Care Excellence (NICE), GlaxoSmithKline (GSK) has high hopes in developing a cure for the virus in the future.

153

153

European Pharmaceutical Review

JUNE 28, 2023

million by 2030, growing at a compound annual growth rate (CAGR) of 5.57 percent from 2023 to 2030. percent between 2023 and 2030. percent from 2023 to 2030. The post HPLC market projected to value $8 million by 2030 appeared first on European Pharmaceutical Review. What is driving the HPLC market?

Drug Development 98

Drug Development Compounding 98

The Pharmacist

JUNE 11, 2024

The Conservative Party has set out spending plans of £250m each year on Pharmacy First from 2027 to 2030, as it pledges to expand the service to include more conditions like acne and chest infections.

Documentation 89

Documentation 89

STAT

FEBRUARY 29, 2024

It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.)

Drug Development 363

Drug Development 363

Express Pharma

MARCH 17, 2023

India is set to become a major player in the global nutraceutical industry, with a projected $100 billion valued market by 2030. For more information, see the report: [link] The post An AI tool to catalyse Mission $100 billion nutraceutical India by 2030 appeared first on Express Pharma.

105

105

STAT

SEPTEMBER 29, 2022

The Covid-19 pandemic set back many of the global health goals for 2030. One of the most feasible to recover is the target of eliminating human deaths from rabies , thanks to an effective, inexpensive vaccine for dogs.

Vaccines 280

Vaccines 280

Express Pharma

NOVEMBER 28, 2024

India’s pharmaceutical market, currently valued at approximately $60 billion, is projected to double by 2030. Getting this right will hold the key to winning a disproportionate market share in a large and expanding value pool (~$12B domestic market for global pharma companies by 2030).

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 105

Express Pharma

APRIL 18, 2023

billion in 2030 at a compound annual growth rate (CARG) of 4.6 GlobalData’s latest report, ‘Multiple Sclerosis: Seven-Market Drug Forecast and Market Analysis to 2030 – Update’ , identified the potential launch of 10 new pipeline products as the main driver of the market’s growth. billion in 2030. billion in 2020 to $29.8

Compounding 98

Compounding 98

European Pharmaceutical Review

JULY 18, 2023

billion by 2030. Digitalisation to boost quality management systems market The post QMS market to value nearly $4b by 2030 appeared first on European Pharmaceutical Review. According to the research, the pharmaceutical quality management systems market is projected to reach $3.97

Documentation 98

Documentation Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 98

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8

Generic Medicine 98

Generic Medicine Chemotherapy 98

Express Pharma

DECEMBER 18, 2024

Indian pharma market is expected to move up to USD 120-130 Billion by 2030 from current size of USD 58 Billion. To capitalise on these opportunities, the industry will continue to focus on building a strong innovation pipeline, enhancing regulatory compliance, and expanding global market.

Biosimilars 98

Biosimilars Vaccines 98

European Pharmaceutical Review

AUGUST 21, 2023

billion by 2030 and grow at a CAGR of 3.84 percent from 2023 to 2030. billion by 2030 appeared first on European Pharmaceutical Review. According to a market report , the global RNA therapy clinical trials market is anticipated to reach $3.5

Vaccines 98

Vaccines 98

STAT

FEBRUARY 12, 2024

Novo Holdings, the controlling shareholder of Novo Nordisk, plans to invest about $35 billion by 2030 , Reuters writes. Novo Holdings would invest about $5 billion a year in the next five years, and that could go up to $7 billion a year by 2030.

Diabetes 282

Diabetes Vaccines Communication Hospitals 282

Express Pharma

DECEMBER 2, 2024

By 2030, half of all US adults are predicted to be obese (New England Journal of Medicine). Morley concludes, “With expected drug sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative market for drug developers. This alarming trend presents a lucrative opportunity for drugmakers.

Labelling 126

Labelling Diabetes Drug Development 126

STAT

JUNE 7, 2024

They are driving a race among drugmakers for a slice of a market that could exceed $100 billion by 2030. Weight loss treatments have the potential to revolutionize health care in rich countries.

251

251

European Pharmaceutical Review

AUGUST 17, 2022

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. According to a recent report , the global formulation development outsourcing market size should grow to $61.4

Compounding 96

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Development 96

BioPharma Dive

MAY 21, 2024

pharma expects to launch 20 new drugs by then, among them complex medicines for cancer as well as treatments for weight loss.

124

124

European Pharmaceutical Review

OCTOBER 7, 2022

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 billion by 2030 appeared first on European Pharmaceutical Review. A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Leading companies in the oral solid dosage market are Catalent, Inc.,

Dosage 98

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 98

STAT

DECEMBER 15, 2022

In a bid to widen access to insulin in primarily low-income nations in Africa, Eli Lilly has agreed to sell active pharmaceutical ingredients and transfer technology to an Egyptian company that expects to supply the life-saving diabetes treatment to as many as 1 million people by 2030.

Diabetes 267

Diabetes Drug Pricing 267

STAT

MAY 18, 2023

Most experts predict that Tennessee will be short 5,989 physicians by 2030 , 1,107 of them primary care doctors. By opening a new pathway for doctors trained outside the United States, HB1312 and SB1451 , introduced by state Rep. Sabi Kumar and state Sen. Kerry Roberts, will help Tennessee address its growing physician shortage.

261

261

STAT

NOVEMBER 12, 2024

AstraZeneca, which is partnered with Daiichi Sankyo on the drug, has cited Dato-DXd as one of the products that will help it achieve its goal of nearly doubling its revenue to $80 billion by 2030.

Chemotherapy 274

Chemotherapy 274

STAT

FEBRUARY 3, 2023

Certification by the Food and Drug Administration that these products are safe and useful against many common ailments could unleash a $60 billion annual market by 2030. But the FDA turned down industry trade groups , and for good reason.

Compounding 246

Compounding 246

STAT

DECEMBER 27, 2023

And you know why: Demand is intense — so intense that, by 2030, the market for these medicines is forecast to hit $41 billion, according to analysts at TD Cowen. The fundamental issues and intriguing stories that characterized the year gone by will to continue to loom.

Drug Pricing 290

Drug Pricing 290